COMMUNIQUÉS West-GlobeNewswire

FDA Grants Fast Track Designation to Merakris’ MTX-001, Opening Potential Accelerated Path to Market for Venous Leg Ulcer Therapy
02/06/2026
Fast Track Designation Provides Opportunities for Rolling BLA Review, Enhanced FDA Engagement, and Earlier Alignment on Manufacturing and Regulatory Requirements RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE [...]
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
02/06/2026
PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will [...]
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
02/06/2026
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD Company to highlight AXPAXLI™ wet [...]
Augustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific Sessions
02/06/2026
Poster will feature in vivo efficacy profile of one of Augustine’s HDAC6 inhibitor development candidates LEUVEN, Belgium – 2 June 2026 – Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company [...]
The Ensign Group Purchases Memory Care Facility in California
02/06/2026
SAN JUAN CAPISTRANO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
02/06/2026
Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief [...]
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
02/06/2026
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable survival benefit: 12-month [...]
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
02/06/2026
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was [...]
Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
02/06/2026
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company [...]
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
02/06/2026
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- [...]
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
02/06/2026
COPENHAGEN, Denmark, June 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the third and final tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 [...]
Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient
02/06/2026
Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient Well-established pharmaceutical technology business of Molecular [...]
Nanobiotix rejoint l'indice Euronext Tech Leaders
02/06/2026
PARIS et CAMBRIDGE, Mass., 02 juin 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Philips announces exchange ratio for 2025 dividend
02/06/2026
June 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2025 is 1 new common share for every 26.9341 existing common shares. [...]
Transactions in connection with share buy-back program
02/06/2026
Company announcement no. 19 - 26 2 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Nanobiotix Joins the Euronext Tech Leaders Index
02/06/2026
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
OXB Capital Markets Event
02/06/2026
OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy market Event to highlight OXB’s proven track record, leading technical capabilities, expanded [...]
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
02/06/2026
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of novel, [...]
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
02/06/2026
Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the [...]

Pages